HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 estimate, narrowing Adicet Bio’s expected loss to $2.05 per share from $2.93. It also reduced its full-year 2026 loss forecast to $8.05 per share from $11.58.
• Despite improving projections, Adicet Bio remains unprofitable: the company recently reported a quarterly loss of $1.99 per share, missing the $1.69 consensus estimate, and analysts expect losses to continue through 2027.
• Analyst sentiment is broadly positive, with an average “Moderate Buy” rating and a $46.80 target price, while institutional investors own approximately 83.89% of the stock.

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - HC Wainwright raised their Q3 2026 earnings estimates for shares of Adicet Bio in a report issued on Monday, August 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.05) per share for the quarter, up from their prior forecast of ($2.93). The consensus estimate for Adicet Bio's current full-year earnings is ($8.52) per share. HC Wainwright also issued estimates for Adicet Bio's Q4 2026 earnings at ($2.12) EPS, FY2026 earnings at ($8.05) EPS, Q1 2027 earnings at ($2.19) EPS, Q2 2027 earnings at ($1.95) EPS, Q3 2027 earnings at ($1.78) EPS, Q4 2027 earnings at ($1.83) EPS and FY2027 earnings at ($7.67) EPS.

Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.99) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.30).

Other research analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of Adicet Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, May 26th. Wall Street Zen raised Adicet Bio from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Jefferies Financial Group initiated coverage on Adicet Bio in a research report on Tuesday, May 5th. They set a "buy" rating and a $19.00 target price for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $90.00 price target (down from $100.00) on shares of Adicet Bio in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $46.80.

Adicet Bio Price Performance

ACET opened at $8.23 on Wednesday. Adicet Bio has a one year low of $6.01 and a one year high of $17.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.71 and a quick ratio of 6.71. The company's 50 day simple moving average is $8.32 and its 200-day simple moving average is $7.81. The stock has a market capitalization of $77.03 million, a P/E ratio of -0.72 and a beta of 1.60.

Institutional Investors Weigh In On Adicet Bio

A number of institutional investors and hedge funds have recently modified their holdings of ACET. NEXTBio Capital Management LP bought a new position in Adicet Bio in the fourth quarter valued at approximately $1,329,000. Luminus Management LLC bought a new stake in shares of Adicet Bio during the 4th quarter valued at $501,000. Burkehill Global Management LP acquired a new position in shares of Adicet Bio in the 4th quarter valued at $526,000. Squarepoint Ops LLC lifted its stake in shares of Adicet Bio by 20.0% in the 4th quarter. Squarepoint Ops LLC now owns 55,723 shares of the company's stock valued at $469,000 after purchasing an additional 9,296 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Adicet Bio in the 3rd quarter valued at $33,000. 83.89% of the stock is owned by institutional investors.

Trending Headlines about Adicet Bio

Here are the key news stories impacting Adicet Bio this week:

• Positive Sentiment: HC Wainwright significantly reduced its loss forecasts for 2026. The firm now expects Adicet Bio to lose $8.05 per share in fiscal 2026, compared with its previous estimate of a $11.58 loss. Its Q3 and Q4 2026 loss estimates were also improved to $2.05 and $2.12 per share, respectively, from $2.93 and $2.99.
• Positive Sentiment: Longer-term estimates also point to gradual improvement. HC Wainwright forecasts a $7.67 per-share loss for fiscal 2027, with quarterly losses narrowing from $2.19 in the first quarter to $1.78 by the third quarter and $1.83 in the fourth quarter.
• Positive Sentiment: Zacks upgraded Adicet Bio to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade could encourage additional near-term buying. All You Need to Know About Adicet Bio Rating Upgrade to Buy
• Neutral Sentiment: Short-interest data provided no meaningful signal. Reported short interest was zero shares, making the stated increase and short-interest ratio unusable for assessing potential short-covering activity.
• Negative Sentiment: Adicet Bio is still expected to post substantial losses. HC Wainwright’s forecasts remain below zero through 2027, while the broader consensus calls for an $8.52 per-share loss in the current year. The company’s recent quarterly loss also exceeded analyst expectations, underscoring continuing execution and financing risks.

About Adicet Bio

Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source